Phathom Pharmaceuticals shares soar on FDA exclusivity grant
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
Guggenheim on Phathom Pharmaceuticals (PHAT): 'Our NPV analysis suggests fair value in the $12-14 range'
June 6, 2025 1:46 PM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $12.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).
The analyst comments "Recall that in Dec 2024, PHAT submitted a Citizen Petition (CP) to the FDA to formally request correction to the Orange Book listings for 10 mg... More
Phathom Pharmaceuticals (PHAT) PT Raised to $29 at Cantor Fitzgerald
June 6, 2025 1:16 PM EDTCantor Fitzgerald analyst Kristen Kluska raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $29.00 (from $23.00) while maintaining a Overweight rating.
... MoreStifel Reiterates Buy Rating on Phathom (PHAT), PT $28, 'We leave our model unchanged, as our view reflected full 10-year exclusivity'
June 6, 2025 12:48 PM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $28.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).
The analyst comments "Voquezna Granted CP and Officially Gains 10-Year Exclusivity, Extending to 2032: Recall, last December PHAT filed a citizens petition/ CP to proactively nudge the FDA to update the Orange... More
